Latest / The Well-Built Life / Miracle Recovery: Selenium’s Fight Against Lung Cancer
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple, practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:23Speaker 1: and let's dive in. Right, let's set the stage. Imagine
- 0:26Speaker 1: a case study that could potentially upend how we think
- 0:29Speaker 1: about treating advanced lung cancer. In 2020, a patient from
- 0:33Speaker 1: Sweden found herself in a dire situation. Advanced treatment, resistant
- 0:39Speaker 1: lung cancer that was projected to have an extremely poor prognosis.
- 0:43Speaker 2: Exacting how dire, exactly. Because it's quite telling when something
- 0:48Speaker 2: so seemingly hopeless shows an unexpected response.
- 0:51Speaker 1: Precisely. The patient was in an advanced stage. with a
- 0:54Speaker 1: life expectancy measured in months. Her condition was so severe
- 0:59Speaker 1: that the clinical team was essentially treating her as if
- 1:02Speaker 1: she were terminal. But then, in a groundbreaking move, she
- 1:05Speaker 1: agreed to participate in a clinical trial using sodium selenite,
- 1:09Speaker 1: a compound known for its role in antioxidant defenses and
- 1:13Speaker 1: immune function.
- 1:14Speaker 2: An interesting choice of therapy. Sodium selenite. Can you walk
- 1:18Speaker 2: us through the mechanism? How does the compound interact with
- 1:22Speaker 2: the body and potentially cancer cells? Sure.
- 1:25Speaker 1: Sodium selenite is naturally occurring in foods like seafood, meat, grains,
- 1:29Speaker 1: and certain nuts. It's vital for the human body's antioxidant
- 1:33Speaker 1: system and immune function. The clinical trial involved administering high
- 1:38Speaker 1: doses of this compound to the patient. The study noted
- 1:41Speaker 1: a significant drop in the patient's soluble PD, L1, a
- 1:46Speaker 1: marker that's typically high in aggressive tumors. but low in
- 1:49Speaker 1: patients with successful immune responses.
- 1:52Speaker 2: The drop in SPD-L1 is key. It suggests a shift
- 1:57Speaker 2: in the tumor's ability to evade the immune system. But
- 2:00Speaker 2: it's the lasting impact that truly blows my mind. The
- 2:04Speaker 2: patient went from being on borrowed time to living cancer,
- 2:08Speaker 2: free for a decade. That's an unprecedented outcome.
- 2:11Speaker 1: Exactly. Which brings up an interesting contradiction. This one case,
- 2:16Speaker 1: while extraordinary... is also incredibly rare. It's a single patient,
- 2:22Speaker 1: not a broad sample size. So how much can we
- 2:25Speaker 1: really generalize from this?
- 2:27Speaker 2: Absolutely. And to raise a whole host of other variables
- 2:31Speaker 2: to consider other treatments, lifestyle factors, you name it. How
- 2:35Speaker 2: do we know this wasn't just a fluke, or even
- 2:38Speaker 2: a result of something else that wasn't accounted for? True.
- 2:41Speaker 1: It raises critical questions about the cause-effect relationship. We see
- 2:46Speaker 1: low SPD L1 levels, but does that mean the selenite
- 2:50Speaker 1: specifically activated an immune response? Or did something else happen?
- 2:55Speaker 1: It's a question that needs to be answered through more
- 2:57Speaker 1: rigorous studies.
- 2:58Speaker 2: That's where the broader medical community comes in. Clinicians, researchers,
- 3:03Speaker 2: and industry are all watching this case with great interest.
- 3:07Speaker 2: Pharmaceutical companies might see this as a promising direction. funding
- 3:12Speaker 2: further research to explore the therapeutic potential of sodium selenite.
- 3:16Speaker 1: And it's not just academics and industry. Advocacy groups are
- 3:20Speaker 1: likely cheering this as a beacon of hope, pushing for
- 3:23Speaker 1: faster clinical trials, with an eye on the ethical implications
- 3:27Speaker 1: of moving so quickly from a single case.
- 3:29Speaker 2: It's a delicate dance between optimism and caution. While the
- 3:33Speaker 2: initial results are exciting, the findings must be replicated in
- 3:37Speaker 2: larger controlled trials. Any rush to judgment could lead to
- 3:40Speaker 2: false hope and ultimately harm patients.
- 3:43Speaker 1: Indeed, the future outlook, as Dr. Anna Larson described it,
- 3:47Speaker 1: suggests an intriguing path forward, but one that requires careful navigation.
- 3:53Speaker 1: Whether sodium selenite can be validated as a viable treatment
- 3:56Speaker 1: for advanced lung cancer remains to be seen, but this
- 4:00Speaker 1: single patient's remarkable journey has certainly opened the door to
- 4:04Speaker 1: further investigation. So, let's delve into the biological mechanisms at
- 4:08Speaker 1: play here. Thomas, can you explain how selenium-based therapy might
- 4:13Speaker 1: impact the tumor? Immune relationship. Especially in light of the
- 4:18Speaker 1: changes observed in SPD-L1 levels?
- 4:22Speaker 2: Absolutely. Rachel, imagine a seesaw between the tumor and the
- 4:26Speaker 2: immune system. Normally, the tumor tries to suppress immune responses
- 4:31Speaker 2: through various mechanisms, one of which is SPD-L1. This protein
- 4:37Speaker 2: acts like a brake. hindering the immune cells from attacking
- 4:40Speaker 2: the tumor. In our case, we see a dramatic reduction
- 4:44Speaker 2: in SPD-L1 levels, which could signify a shift in that balance.
- 4:48Speaker 1: That's fascinating. Could you elaborate more on why this might happen?
- 4:53Speaker 1: I mean, how does sodium selenite interfere with the tumor's
- 4:57Speaker 1: ability to suppress immune responses?
- 5:00Speaker 2: Well, think of selenium as a key that unlocks a
- 5:03Speaker 2: new pathway in the immune cells. Normally, the tumor cells
- 5:06Speaker 2: express high levels of SPD-L1 to hijack the immune system.
- 5:11Speaker 2: But when the patient takes selenium, the immune cells start
- 5:14Speaker 2: to recognize the tumor more effectively. The exact mechanism isn't
- 5:18Speaker 2: fully understood, but it likely involves enhancing the activity of
- 5:22Speaker 2: immune cells or directly dampening the suppressive effects of the tumor.
- 5:27Speaker 1: That's a nuanced detail. So, the tumor's brakes are being pushed, essentially.
- 5:33Speaker 1: Does this mean that the immune system's response to the
- 5:35Speaker 1: tumor is amplified as a result?
- 5:38Speaker 2: Precisely. When SPD-L1 levels drop, the immune system can start
- 5:43Speaker 2: to target and eliminate the tumor more efficiently. In the
- 5:46Speaker 2: patient's case, this appears to have resulted in a complete remission.
- 5:51Speaker 2: The key here is that sodium selenite might reset the
- 5:54Speaker 2: regulatory balance, allowing the immune system to regain control.
- 5:58Speaker 1: And do we know if this effect is consistent across
- 6:01Speaker 1: other patients? or is it more specific to this individual?
- 6:05Speaker 2: That's the big question, isn't it? Right now, the findings
- 6:09Speaker 2: are based on a single case, which makes it hard
- 6:11Speaker 2: to draw broad conclusions. However, the significant decrease in SPD
- 6:17Speaker 2: L1 levels in this patient does suggest that the therapy
- 6:20Speaker 2: might have broader applicability. We just need larger studies to
- 6:24Speaker 2: confirm this.
- 6:25Speaker 1: Exactly, which brings up an interesting contradiction. While the results
- 6:29Speaker 1: are promising, The single-case nature of this study limits its generalizability.
- 6:35Speaker 1: How do you think researchers and the broader community should proceed?
- 6:38Speaker 2: Good question. Researchers should definitely aim to replicate these results
- 6:42Speaker 2: in a controlled trial setting to ensure the findings hold up.
- 6:47Speaker 2: But beyond that, we need to understand the underlying biology.
- 6:51Speaker 2: If these results in the broader population can be confirmed,
- 6:55Speaker 2: then the potential for a new treatment could be transformative.
- 6:58Speaker 2: It's like walking a tightrope between hope and caution.
- 7:01Speaker 1: That's a great metaphor. It's all about balancing optimism with
- 7:06Speaker 1: the need for rigorous science. So, where do we go
- 7:08Speaker 1: from here? What kind of studies are necessary to validate
- 7:12Speaker 1: these findings and explore the potential of selenium-based therapy?
- 7:17Speaker 2: Well, we need randomized, controlled trials to see if other
- 7:20Speaker 2: patients can achieve similar outcomes. We also need to investigate
- 7:25Speaker 2: the exact mechanisms and potential side effects of high-dose selenite. And,
- 7:30Speaker 2: of course, we should explore whether this therapy could be
- 7:33Speaker 2: combined with other treatments to maximize its effectiveness.
- 7:36Speaker 1: That sounds like a comprehensive approach. Thanks for breaking this down, Thomas.
- 7:42Speaker 1: It's clear that here is a lot to learn, but
- 7:44Speaker 1: the initial results are indeed promising.
- 7:47Speaker 2: Agreement all around, Rachel. It's an exciting field and we
- 7:51Speaker 2: are just scratching the surface.
- 7:53Speaker 1: Thomas, let's dive into the perspectives of the key stakeholders
- 7:57Speaker 1: involved in this case. How do researchers and clinicians view
- 8:01Speaker 1: the validity of such a single case study?
- 8:04Speaker 2: Exactly, Rachel. Researchers initially might see this as a fascinating anomaly,
- 8:09Speaker 2: but it's not the norm to base major claims on
- 8:11Speaker 2: one patient. They would want to replicate these results, right?
- 8:15Speaker 1: Right. And let's not forget... When you have a single-case
- 8:19Speaker 1: study like this, it's crucial to look at the details,
- 8:22Speaker 1: like the patient's unique background and medical history. Does this
- 8:27Speaker 1: make the results more or less credible?
- 8:29Speaker 2: Good point. We could imagine the patient having some other
- 8:32Speaker 2: factors that might have contributed to the outcome, like other
- 8:35Speaker 2: treatments or lifestyle changes. This is why researchers need to
- 8:39Speaker 2: conduct larger controlled trials to see if these results can
- 8:42Speaker 2: be replicated.
- 8:43Speaker 1: Speaking of which, what about the patient advocates? How do
- 8:47Speaker 1: they view this single case study, and what potential benefits
- 8:50Speaker 1: do they see?
- 8:51Speaker 2: Patient advocates might see this as a breakthrough, pushing for
- 8:54Speaker 2: faster clinical trials. But they'd also be wary of the
- 8:57Speaker 2: risks involved if they haven't been fully vetted. They might
- 9:00Speaker 2: call for more transparency and better informed consent processes.
- 9:04Speaker 1: That's insightful. And when we look at the broader implications,
- 9:08Speaker 1: how does the medical community at large view this case?
- 9:12Speaker 1: Do they see it as a stepping stone? Or do
- 9:14Speaker 1: they remain skeptical?
- 9:16Speaker 2: Well, the medical community is likely to be cautious. They
- 9:20Speaker 2: will need to see more evidence before they are willing
- 9:22Speaker 2: to change their treatment protocols. But this case has definitely
- 9:27Speaker 2: sparked interest and could lead to more funding and research
- 9:31Speaker 2: into selenium as an anti-tumor agent.
- 9:33Speaker 1: Indeed. So, how do you think this single case study
- 9:37Speaker 1: could shape future research directions.
- 9:40Speaker 2: It could accelerate research in this area, but only if
- 9:43Speaker 2: it's combined with rigorous methodological standards. We need to figure
- 9:47Speaker 2: out the mechanisms and potential side effects, especially with high-dose selenite,
- 9:51Speaker 2: to ensure its safety and efficacy.
- 9:54Speaker 1: Agreed. And what role can industry play in all of this?
- 9:58Speaker 1: Do you think they will view this single case as
- 10:01Speaker 1: an opportunity to invest more in research and development?
- 10:05Speaker 2: Industries like pharmaceuticals might see potential here, but they will
- 10:09Speaker 2: likely keep a cautious eye. They will want to see
- 10:13Speaker 2: more evidence before committing significant resources. But if the results
- 10:17Speaker 2: hold up, they could certainly push for faster development and
- 10:20Speaker 2: approval processes.
- 10:21Speaker 1: That's a balanced view. So, in the grand scheme of things,
- 10:26Speaker 1: how do you think this case will influence the field
- 10:28Speaker 1: of cancer research and treatment?
- 10:30Speaker 2: It could lead to a paradigm shift in how we
- 10:32Speaker 2: think about cancer therapy, especially for advanced cases where conventional
- 10:36Speaker 2: treatments have failed. But the journey is far from over.
- 10:40Speaker 2: We need more data to back up these initial findings.
- 10:42Speaker 1: Thanks, Thomas. It's clear that while this single case is promising,
- 10:47Speaker 1: We need to tread carefully and gather more evidence. We
- 10:50Speaker 1: will keep the momentum going and see where this research
- 10:53Speaker 1: leads us. So, let's turn our focus to the future
- 10:56Speaker 1: directions this case opens up. Dr. Anna Larson from the
- 11:00Speaker 1: research team said the patient's response was exceptionally prolonged, which
- 11:05Speaker 1: is really intriguing. But what challenges do we face in
- 11:08Speaker 1: translating this to a broader patient population?
- 11:11Speaker 2: Right, that's the million-dollar question. Dr. Lars Engstrom echoed the
- 11:15Speaker 2: need for further studies. Mentioning that larger controlled trials are
- 11:19Speaker 2: needed to confirm these findings. But let's break down why
- 11:23Speaker 2: such an elaborate study is so crucial. What are the
- 11:26Speaker 2: specific challenges in conducting these trials? Rachel?
- 11:30Speaker 1: Well, Thomas, it's about more than just the numbers. We
- 11:33Speaker 1: need to address the single-case study nature. Dr. Maria Svensson
- 11:38Speaker 1: highlighted that larger trials are necessary to understand the potential
- 11:41Speaker 1: broader applicability of selenite. The current case is a fascinating anomaly.
- 11:46Speaker 1: but we can't base our new treatments on anomalies. We
- 11:49Speaker 1: need hard evidence.
- 11:51Speaker 2: Exactly. That's the elephant in the room, the single-case study.
- 11:55Speaker 2: How do we ensure that the observed effects aren't just
- 11:58Speaker 2: an outlier? To raise also the issue of reproducibility, we
- 12:02Speaker 2: need to recreate this outcome in a diverse patient group.
- 12:06Speaker 2: But even beyond that, how do we know the selenite
- 12:09Speaker 2: isn't just lucky?
- 12:10Speaker 1: Great point. So, let's dig into the specific challenges. For one,
- 12:15Speaker 1: we need to understand more about the mechanisms. Dr. Larson
- 12:19Speaker 1: identified that the prolonged response raises questions about selenium's impact
- 12:24Speaker 1: on the tumor-immune interaction. But we need to clarify, how
- 12:28Speaker 1: does selenite interact with the immune system to potentially inhibit
- 12:32Speaker 1: tumor growth? This gets technical, but it's crucial.
- 12:36Speaker 2: Absolutely. It's not just about proving the therapy works. We
- 12:40Speaker 2: need to understand the why. That's where the deeper scientific
- 12:43Speaker 2: inquiry comes in. We need to look at the baseline SPD,
- 12:48Speaker 2: L1 levels, the significant decrease post-treatment, and explore correlations with
- 12:53Speaker 2: immune function and tumor behavior. This complexity is why we
- 12:57Speaker 2: are calling for larger placebo-controlled trials.
- 13:01Speaker 1: Right. Speaking of which, what role do we see for
- 13:04Speaker 1: industry players here? Pharmaceutical companies and funding bodies might see
- 13:08Speaker 1: this promise and want to invest. But Therese also, the
- 13:12Speaker 1: ethical angle public and patient advocates might push for faster
- 13:16Speaker 1: clinical trials, which raises questions about patient consent and the
- 13:20Speaker 1: speed versus safety trade-offs.
- 13:22Speaker 2: That's a crucial balance to strike. On one hand, we
- 13:25Speaker 2: want to accelerate progress in treatment, which is understandable given
- 13:29Speaker 2: the severity of the situation. On the other hand, safety
- 13:32Speaker 2: must be the top priority. The current state of research
- 13:36Speaker 2: points to a promising avenue, but we can't jump the gun.
- 13:39Speaker 2: We need to ensure we get all the facts before
- 13:42Speaker 2: any wide-scale application. Agreed.
- 13:45Speaker 1: The future outlook is definitely promising, but it comes with
- 13:48Speaker 1: a host of challenges. If larger, rigorous studies confirm the
- 13:52Speaker 1: initial findings, sodium selenite could be a game-changer for advanced
- 13:56Speaker 1: lung cancer patients. But until then, we need to stay grounded,
- 14:01Speaker 1: address the open questions, and be careful not to overlook
- 14:04Speaker 1: the nuances. That brings us to the heart of the matter.
- 14:07Speaker 1: The case of the Swedish patient indeed opens up exciting avenues,
- 14:12Speaker 1: but let's not lose sight of the complexities. The single-case
- 14:16Speaker 1: nature of this study is both a testament and a caution.
- 14:20Speaker 2: Right. It's like finding a rare gem, but one that
- 14:23Speaker 2: could be a fluke. We need to dig deeper to
- 14:25Speaker 2: understand if the treatment truly works for others in similar positions.
- 14:29Speaker 1: Absolutely. One thing to consider is the mechanisms at play.
- 14:34Speaker 1: we saw a significant drop in SPD L1 levels, hinting
- 14:39Speaker 1: at an immune system boost. But, as Dr. Engstrom noted,
- 14:44Speaker 1: we need larger, controlled trials to confirm this.
- 14:47Speaker 2: Exactly, like checking if the gem is actually valuable, not
- 14:52Speaker 2: just glittery, and we can't ignore the potential toxicity. Dr.
- 14:56Speaker 2: Svensson highlighted the need for stringent, placebo-controlled trials.
- 15:01Speaker 1: Indeed, these trials are critical. They will help us understand
- 15:05Speaker 1: if the treatment is safe and effective. But even if
- 15:08Speaker 1: they confirm the results, we must proceed with caution. This
- 15:13Speaker 1: doesn't mean sodium selenite works for everyone.
- 15:16Speaker 2: True. What about the skeptics in the medical community? They
- 15:20Speaker 2: might need some convincing. But on the flip side, how
- 15:24Speaker 2: do we balance the hope for patients with the need
- 15:26Speaker 2: for rigorous science?
- 15:28Speaker 1: A delicate balance. We should encourage faster research. but ensure
- 15:32Speaker 1: it's done with integrity. This involves involving patient advocates, ensuring transparency,
- 15:39Speaker 1: and keeping an open dialogue between researchers and the public.
- 15:43Speaker 2: Exactly. It's a matter of moving forward with open eyes.
- 15:47Speaker 2: We need more detailed studies to back up the initial findings. But,
- 15:51Speaker 2: at the same time, we shouldn't dismiss the potential for
- 15:54Speaker 2: a promising therapy.
- 15:55Speaker 1: And we should remember that even if the future outlook
- 15:58Speaker 1: looks promising, we can't jump the gun. The rigor of
- 16:01Speaker 1: the studies must come first. That's why it's important to
- 16:04Speaker 1: continue monitoring the patient and conducting more robust research.
- 16:08Speaker 2: Agreed. Let's keep pushing for more data. The journey to
- 16:12Speaker 2: a safer, more effective treatment is long, but the potential
- 16:16Speaker 2: benefits are significant. Indeed.
- 16:18Speaker 1: For now, we must maintain a balanced approach, promising, but cautious.
- 16:24Speaker 1: The future of sodium selenite as a cancer therapy is uncertain.
- 16:28Speaker 1: but certainly worth exploring further. That brings us to the
- 16:31Speaker 1: end of today's episode. Thank you so much for spending
- 16:34Speaker 1: part of your day with me. If you found this
- 16:37Speaker 1: episode's tips helpful and want to make sure you don't
- 16:39Speaker 1: miss the next conversation, please take a quick second to
- 16:42Speaker 1: hit that subscribe or follow button on whatever platform you
- 16:46Speaker 1: are listening on. It's a completely free way to support
- 16:49Speaker 1: the show and helps more people find us. This podcast
- 16:52Speaker 1: is independently produced, so if you are ever in a
- 16:55Speaker 1: position where you would like to help keep it running,
- 16:58Speaker 1: We do accept small donations. You can find a link
- 17:01Speaker 1: right in the episode description below to buy us a
- 17:03Speaker 1: coffee or contribute what you can. Every bit genuinely helps.
- 17:08Speaker 1: Take care of yourself, stay balanced, and we will talk
- 17:11Speaker 1: again soon.